Focus: Element Biosciences is a San Diego-based biotech company specializing in genetic analysis and sequencing tools for rare disease applications. The company operates at Series C+ stage with active commercialization efforts across 16 open roles.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Stable — net -3 jobs in 30d
5 added, 8 removed. Backfill posture.
Best fit for careers in commercialization, customer success, or bioinformatics supporting sequencing platforms; limited appeal for drug development-focused candidates.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Element Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Element Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: KALA BIO, Inc. (KALA) (CIK 0001479419) — EXHIBIT 10.1
EXHIBIT 10.1
Up and down the ladder: The latest comings and goings - statnews.com
Up and down the ladder: The latest comings and goings statnews.com
Pharma Races to Scale AI as Billions Flow into Drug Discovery - Genetic Engineering and Biotechnology News
Pharma Races to Scale AI as Billions Flow into Drug Discovery Genetic Engineering and Biotechnology News
Pharma Races to Scale AI as Billions Flow into Drug Discovery - Genetic Engineering and Biotechnology News
Pharma Races to Scale AI as Billions Flow into Drug Discovery Genetic Engineering and Biotechnology News
Samsung bets on multiomics, challenges Illumina with Element stake - CHOSUNBIZ - Chosunbiz
Samsung bets on multiomics, challenges Illumina with Element stake - CHOSUNBIZ Chosunbiz
AI and Automation Reshape Biotech... Global Investment in Innovative Biopharma Technologies Expands - 아시아경제
AI and Automation Reshape Biotech... Global Investment in Innovative Biopharma Technologies Expands 아시아경제
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo